Liquidia wins FDA Fast Track for YUTREPIA in SSc—RP
Liquidia (LQDA) received FDA Fast Track for YUTREPIA inhalation powder in SSc—RP. The company is preparing a ~75-patient Phase 2a RE—WARM trial, enrolling Oct 2026 and targeting primary completion Feb 2027.
Liquidia Corporation (NASDAQ:LQDA) said YUTREPIA inhalation powder won FDA Fast Track designation for systemic sclerosis-associated Raynaud’s phenomenon, or SSc—RP. The company said it is preparing a Phase 2a RE—WARM trial in about 75 patients, with enrollment planned for Oct 2026 and primary completion expected in Feb 2027. S. addressable market of about 30,000 patients.